Phase II clinical trial which will include all patients diagnosed with chronic anterior
myocardial infarction (more than 6 months from the acute phase and the complete
revascularization in which it is assessed the evolution of left ventricular function in
patients to the monitoring against their own basal condition.
Included patients will be studied in the following conditions:
- Basal condition: defined as the immediately preceding to the administration of cell
- Monitoring Condition 1: three months after drug administration of cell therapy. Includes
non-invasive methods of exploration of ventricular function.
- Monitoring Condition 2: six months after administration of treatment. Includes the same
methods of exploration of ventricular function practised in the basal condition,
including cardiac catheterism as well as non invasive methods.
- Monitoring Condition 3: twelve months after administration of the cell therapy drug.
Includes non-invasive methods of exploration of ventricular function.
The trial hypothesis we propose consists of mononuclear cells of bone marrow providing
progenitor cells with regenerative capacity and also secreting several angiogenic factors,
and their implantation into ischemic tissues should contribute with both elements to the
angiogenesis and tissue regeneration with myocardial functional recovery